

Corvus Pharmaceuticals shares interim Phase 1 trial data showing promising results for soquelitinib in treating moderate to severe atopic dermatitis.
You can purchase shares of Corvus Pharmaceuticals (NASDAQ:CRVS) through any online brokerage.
Other companies in Corvus Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Corvus Pharmaceuticals has a consensus price target of $28.86.
The stock price for Corvus Pharmaceuticals (NASDAQ: CRVS) is $10.45 last updated October 27, 2026 at 7:11 AM EDT.
There are no upcoming dividends for Corvus Pharmaceuticals.
Corvus Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Corvus Pharmaceuticals.
Corvus Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad...